Most recent update: Tuesday, December 10, 2019 - 11:08

Bariatric News - Cookies & privacy policy

You are here

mini gastric bypass

Single-anastomosis bypass – an attractive alternative?

The mortality rate was reported at 0.0%–0.18% with a 30-day morbidity rate of 2.7% to 6.7%
The resolution of T2DM varied between 70% and 100%

According to a paper published in the Scandinavian Journal of Surgery, the single-anastomosis gastric bypass “may be an attractive alternative metabolic operation”. Also known as the one-anastomosis gastric bypass or mini gastric bypass, the procedure can result in a shorter operative time, fewer short- and long-term complications, improved and sustained excess weight loss and is more effective in terms of resolutions of comorbidities compared to standard RYGB, the paper states.

Introduced by Dr Robert Rutledge in 2001, the single-anastomosis bypass has increased in popularity due to its simplicity and apparent safety and effectiveness. The benefits include:

  • fewer sites for leakage and internal hernia
  • easier and faster to learn and perform
  • easier to reverse and revise

Mikael Victorzon

Despite such benefits, the author of the paper, Professor Mikael Victorzon from Vaasa Central Hospital, Vaasa, Finland, warns there is a risk of symptomatic biliopancreaticoduodenal reflux, iron deficiency anaemia and marginal ulcers, and further studies with vigorous long-term follow-up are required.

Therefore, he undertook a literature review to ascertain current date on the clinical outcomes. In total, he identified 73 articles and after removal of case studies, duplicates, and irrelevant articles, ten articles remained for closer review, including only one randomised study (in total 7,287 patients).


In terms of morbidity, mortality, conversion rates, los, and follow-up, from the fivecentres with ~1,000 or more patients, the mortality rate is reported at 0.0%–0.18%, with a 30-day morbidity rate of 2.7% to 6.7%, leakage (from the gastric tube or anastomosis) rate as 0.2%–1.3%, conversion 0.0% and 1.2%, mean operative time between 37.5 and 115.3 min. The mean hospital length of stay was between one and four days. Victorzon notes that the follow-up rate of 5–6 years is “incomplete in most studies”, varying between 56% and 84%. Excessive weight loss occurred in 0.1%–1.28% of the patients.

Table 1: Mortality, morbidity, operative time, length of stay (LOS), follow-up (FU) as reported by the authors.

With regards to the resolution of comorbidities, remission of type 2 diabetes (T2DM) varies between 70% and 100%; hypertension between 80% and 98.5%; hyperlipidaemia remission between 70% and 100%; and sleep apnoea 87%–100%

Table 2: Resolutions of comorbidities as reported by the authors.

Considering late complications, Victorzon report that the incidence of marginal ulcers was reported as 0.6%–5.6% and iron deficiency anaemia occurred in 4.9%–7.6% of patients.

“Although to date no cases of gastric or oesophageal cancers have been reported in humans after MGB, we have to remember the relatively small number of patients and short follow-up so far when evaluating the significance of this fact,” adds Victorzon. “The MGB may be an attractive alternative metabolic operation gaining in popularity worldwide. Several relatively large series and one RCT all report fairly similar results; shorter operative time, fewer short- and long-term complications, shorter LOS, better EWL and better sustained EWL at least during mid-term follow-up, and more effective in terms of resolutions of comorbidities compared to standard RYGB. Further studies with robust, long-term follow-up are needed.”

To access this paper, please click here

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.